Financial Performance - The group's unaudited revenue for the six months ended June 30, 2021, was approximately SGD 4,623,000, an increase of about SGD 1,289,000 or 38.7% compared to SGD 3,334,000 for the same period in 2020[5]. - The group reported an unaudited loss of approximately SGD 2,829,000 for the six months ended June 30, 2021, an increase of about SGD 1,776,000 or 169% compared to a profit of SGD 1,053,000 for the same period in 2020[5]. - For the six months ended June 30, 2021, the company reported a total comprehensive loss of SGD 2,829,000, compared to a total comprehensive loss of SGD 993,000 for the same period in 2020[11][13]. - The company reported a pre-tax loss of SGD 2,829,000 for the six months ended June 30, 2021, compared to a loss of SGD 1,053,000 in the same period in 2020, representing an increase in losses of approximately 168.5%[54]. - Basic loss per share for the six months ended June 30, 2021, was SGD 0.40, compared to SGD 0.17 for the same period in 2020, indicating a worsening in per-share performance[54]. Revenue Breakdown - Revenue from medical services reached SGD 4,623 thousand for the six months ended June 30, 2021, compared to SGD 3,334 thousand for the same period in 2020, representing a year-over-year increase of approximately 38.6%[45]. - Revenue from beauty services was SGD 231 thousand, while consultation services generated SGD 946 thousand, and prescription and dispensing services contributed SGD 1,406 thousand for the first half of 2021[45]. - Revenue from consultation services increased from SGD 665,000 for the six months ended June 30, 2020, to SGD 946,000 for the same period in 2021, reflecting an increase of 281,000 or 42.3%[91]. - Revenue from prescription and dispensing services rose from SGD 1,008,000 to SGD 1,406,000, an increase of SGD 398,000 or 39.4%[91]. - Revenue from treatment services increased from SGD 977,000 to SGD 1,267,000, a rise of SGD 290,000 or 29.6%[91]. - Other services revenue grew from SGD 340,000 to SGD 718,000, an increase of SGD 378,000 or 111.2%[92]. Expenses and Costs - Employee benefit expenses amounted to approximately SGD 2,689,000, an increase of about SGD 1,728,000 or 179.8% compared to SGD 961,000 for the same period in 2020[5]. - The company incurred professional and consulting expenses of SGD 1,623,000 for the six months ended June 30, 2021, slightly down from SGD 1,630,000 in the same period of 2020[51]. - Other operating expenses increased by approximately SGD 571,000 or 29% to SGD 2,562,000 for the six months ended June 30, 2021[104]. Assets and Liabilities - Total assets less current liabilities amounted to SGD 14,287,000 as of June 30, 2021, compared to SGD 12,118,000 as of December 31, 2020[9]. - The net assets of the company were SGD 7,199,000 as of June 30, 2021, compared to SGD 5,531,000 as of December 31, 2020[9]. - Current liabilities totaled SGD 10,242,000 as of June 30, 2021, compared to SGD 9,626,000 as of December 31, 2020[9]. - The company's cash and cash equivalents decreased to SGD 4,871,000 as of June 30, 2021, down from SGD 7,639,000 at the end of June 2020[13]. - The company recorded a net cash outflow from operating activities of approximately SGD 1,996,000 for the six months ended June 30, 2021, compared to SGD 2,928,000 for the same period in 2020[114]. Shareholder Information - The board does not recommend the payment of an interim dividend for the six months ended June 30, 2021[5]. - The company did not recommend an interim dividend for the six months ended June 30, 2021, consistent with the previous year[55]. - As of June 30, 2021, Dr. Loh Teck Hiong holds 278,848,000 shares, representing 38.73% of the company's equity[129]. - Brisk Success Holdings Limited, controlled by Dr. Loh, is the beneficial owner of the 278,848,000 shares, also accounting for 38.73% of the company's equity[131]. Strategic Initiatives - The company plans to diversify its services and product offerings through acquisitions, particularly in Hong Kong, the Greater Bay Area, Singapore, and ASEAN countries[118]. - The group anticipates a strong rebound in profitability in 2021 due to the easing of COVID-19 restrictions and rapid vaccination rollout[87]. - The company plans to strategically expand clinics outside of Singapore with an investment of around HKD 1.0 million, expecting significant revenue contributions post-vaccination in Hong Kong[126]. Compliance and Governance - The company has complied with all applicable corporate governance codes during the six months ending June 30, 2021[134]. - All directors confirmed compliance with the trading code during the six months ending June 30, 2021[141]. - The company has adhered to the non-competition commitments made by its controlling shareholders as of June 30, 2021[143].
德斯控股(08437) - 2021 - 中期财报